Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta-Analysis [0.03%]
达雷妥尤单抗、来那度胺和地塞米松与硼替佐米、来那度胺和地塞米松用于不适合移植的新诊断多发性骨髓瘤的治疗：系统文献回顾和meta分析
Lucio N Gordan,Rohan Medhekar,Alex Z Fu et al.
Lucio N Gordan et al.
Daratumumab in combination with lenalidomide and dexamethasone (DRd) and bortezomib in combination with lenalidomide and dexamethasone (VRd) are guideline-recommended preferred regimens for initial treatment of transplant-ineligible (TIE) p...
Meta-Analysis
Hematological oncology. 2025 May;43(3):e70061. DOI:10.1002/hon.70061 2025
Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs [0.03%]
我的纤维化治疗：匹配治疗方法的进展与临床需求
Chan Tze Wei,Hein Than,Feng-Ju Huang et al.
Chan Tze Wei et al.
Myelofibrosis (MF) is characterized by anemia, constitutional symptoms, hepatosplenomegaly and bone marrow fibrosis, and is associated with poor survival. The janus kinase inhibitor (JAKi) ruxolitinib has been the mainstay of treatment for ...
Detection of Hematological Malignancies Using N-NOSE (Nematode-NOSE) [0.03%]
使用N-NOSE（线虫-NOSE）检测血液恶性肿瘤
Shingen Nakamura,Hideyuki Hatakeyama,Sumiko Yoshida et al.
Shingen Nakamura et al.
Hematological malignancies often lack defined risk factors and present with non-specific symptoms, underscoring the urgent need for simple and reliable detection methods. To address this challenge, Hirotsu et al. innovated N-NOSE, a novel, ...
Rapid and Sensitive Detection of the MYD88 L265P Mutation for Lymphoplasmocytic Lymphoma/Waldenström's Macroglobulinemia via CRISPR-Cas12a [0.03%]
利用CRISPR-Cas12a对淋巴浆细胞淋巴瘤/瓦登斯特伦巨球蛋白血症中的MYD88 L265P突变进行快速敏感的检测
Rumei Sun,Xiaping Miao,Qingyang Jiang et al.
Rumei Sun et al.
Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching-Adjusted Indirect Analysis [0.03%]
瑞马卡布塔吉仑自体白细胞与常规治疗在复发/难治性滤泡性淋巴瘤中的生存获益：一项匹配调整的间接分析
Fenghua Gao,Cong Sun,Jing Liu et al.
Fenghua Gao et al.
Little is known about the survival benefit of relmacabtagene autoleucel (relma-cel) in the current therapeutic landscape of relapsed/refractory (r/r) follicular lymphoma (FL). The current study compared the survival outcomes of Chinese FL p...
Observational Study
Hematological oncology. 2025 Mar;43(2):e70051. DOI:10.1002/hon.70051 2025
Gene Expression Profiling in Acute Myeloid Leukemia Patient Subgroups With High and Low Sensitivity Toward SYK Inhibitors [0.03%]
SYK抑制剂敏感性和耐药性急性髓细胞白血病患者亚组的基因表达特性分析
Marte Karen Brattås,Franziska Görtler,Silje Johansen et al.
Marte Karen Brattås et al.
Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by the uncontrolled proliferation of myeloid cells, and despite recent treatment advances, patient outcomes remain suboptimal. The cytoplasmic spleen tyrosine kinase (...
Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High-Risk MDS Treated With Nucleoside Analogs [0.03%]
核苷类似物治疗AML或高危MDS患者的CDA动力学对临床结果的影响
Erwann Collomb,Laurent Bourguignon,Antoine Tichadou et al.
Erwann Collomb et al.
Comprehensive Analysis of Single-Cell and Bulk Transcriptomics Identified Regulatory T-Cell Features as Predictors of Prognosis in Diffuse Large B-Cell Lymphoma [0.03%]
单细胞和大量转录组的综合分析确定了T调节细胞特征可作为弥漫性大B细胞淋巴瘤预后预测指标
Yaoli Cui,Ge Hu,Xue Han et al.
Yaoli Cui et al.
Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous malignancy. Advances in transcriptomic and genetic profiling have significantly enhanced our understanding of the disease's intrinsic pathogenesis, uncover...
Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC Subtype [0.03%]
PIM激酶的靶向显示了在弥漫性大B细胞淋巴瘤ABC亚型中单药有效性和与BCL2抑制剂的协同作用
Chiara Tarantelli,Omar Kayali,Elisa Civanelli et al.
Chiara Tarantelli et al.
The PIM family of serine/threonine kinases (PIM1, PIM2, and PIM3) are involved in the development of cancer and represent promising therapeutic targets. We investigated the therapeutic potential of targeting PIM kinases in diffuse large B-c...
Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real-World Experience [0.03%]
OEPA/COPDAC方案在儿童和青少年霍奇金淋巴瘤中毒性和耐受性的实际情况研究
Hala Bekhit,Louay Eldeeb,Emad Moussa et al.
Hala Bekhit et al.
Vincristine, etoposide, prednisone, and doxorubicin (OEPA)/cyclophosphamide, vincristine, prednisone, and dacarbazine (COPDAC) regimen represents a preferred chemotherapy backbone for response-adapted treatment of pediatric Hodgkin Lymphoma...